In this episode [13:25], Medicom’s correspondent covers 6 presentations from the annual United European Gastroenterology Week (UEGW 2024), held in Vienna, Austria from 12-15 October 2024.
The topics discussed are:
- Cendakimab meets primary endpoints in eosinophilic oesophagitis
Cendakimab outperformed placebo in patients with eosinophilic oesophagitis across various efficacy endpoints in a phase 3 study. These results were consistent in the sub-population of steroid-refractory patients. - TACITO: Does FMT improve ICI plus VEGFR TKI therapy in mRCC?
Patients with metastatic renal cell carcinoma appeared to experience an additional benefit from targeted faecal microbiota transplantation on top of their regimen of pembrolizumab plus axitinib, in the phase 2 TACITO trial. - Tradipitant improves symptoms of motion sickness
The investigational agent tradipitant successfully reduced the incidence of nausea and vomiting associated with motion sickness in a clinical trial. Both the low dose and the high dose were well-tolerated according to the authors. - Encouraging results for L-carnitine in non-alcoholic fatty liver disease
L-carnitine was associated with improvements in markers of non-alcoholic fatty liver disease when this intervention was compared with lifestyle advice in a randomised clinical trial. - An accelerated treatment approach may save lives in pancreatic walled-off necrosis
An accelerated treatment algorithm appeared to benefit patients with large pancreatic walled-off necrosis in terms of length-of-stay in the hospital and major complications compared with the standard endoscopic step-up approach, according to interim results of the ACCELERATE trial. - TL1A inhibitor tulisokibart shows potential in ulcerative colitis
In the extension period of the phase 2 ARTEMIS-UC study, tulisokibart displayed durable improvements in clinical and endoscopic outcomes in patients with moderately to severely active ulcerative colitis. A phase 3 programme has been launched to assess this agent in a larger population of patients.
Enjoy listening!
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« The current state of digital pathology, molecular diagnostics and biobanking in renal cancer: Kidney Cancer Association Consensus Statement Next Article
No OS benefit of niraparib maintenance in high-risk ovarian cancer »
« The current state of digital pathology, molecular diagnostics and biobanking in renal cancer: Kidney Cancer Association Consensus Statement Next Article
No OS benefit of niraparib maintenance in high-risk ovarian cancer »
Table of Contents: UEGW 2024
Featured articles
Cendakimab meets primary endpoints in eosinophilic oesophagitis
IBD: New Drugs, Established Agents, and Prevention
LOVE-CD: Vedolizumab yields better outcomes in early than in late CD
Moving towards the prevention of IBD
New insights into perianal fistulising CD pathogenesis may lead to new therapies
Risankizumab influences key pathogenic Th17 cells in CD
Meaningful corticosteroid-sparing effect of mirikizumab in UC
Extending ustekinumab dosing interval does not influence drug survival in IBD
CULTIVATE: Promising signal for etrasimod in Crohn’s disease
Tamuzimod delivers promising long-term data in UC
TL1A inhibitor tulisokibart shows potential in UC
Upadacitinib associated with normalisation of HRQoL in UC
Pancreas: Improved Diagnostics and Treatment Algorithms
Diagnostic accuracy of fluorescence confocal laser microscopy after EUS-TA
An accelerated treatment approach may save lives in pancreatic walled-off necrosis
Irritable Bowel Syndrome: from Guar Gum to Tradipitant
Guar gum alleviates IBS-related constipation in a randomised controlled trial
How useful is colonoscopy for constipation in young women?
Liver: Exploring New Therapeutics
Encouraging results for L-carnitine in metabolic dysfunction-associated steatotic liver disease
Other Late-breaking Studies from UEGW
TACITO: Does faecal microbiota transplantation improve survival in mRCC?
Is faecal microbiota transplantation a viable option to treat primary C. difficile infections?
Cendakimab meets primary endpoints in eosinophilic oesophagitis
Related Articles
October 23, 2019
Obeticholic acid prevents liver fibrosis from NASH
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com